FINWIRES · TerminalLIVE
FINWIRES

AstraZeneca's Breast Cancer Drug Rejected by FDA on Safety Concerns, Bloomberg Reports

By

Price: $188.16, Change: $+2.96, Percent Change: +1.60%

Related Articles